Source: The Lancet. Unidade: FMRP
Subjects: DERMATOPATIAS, MIOSITE
ABNT
RUPERTO, Nicolino et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. The Lancet, v. 387, n. 10019, p. 671-678, 2016Tradução . . Disponível em: https://doi.org/10.1016/s0140-6736(15)01021-1. Acesso em: 03 maio 2024.APA
Ruperto, N., Pistorio, A., Oliveira, S., Zulian, F., Cuttica, R., Ravelli, A., et al. (2016). Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. The Lancet, 387( 10019), 671-678. doi:10.1016/s0140-6736(15)01021-1NLM
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Ferriani VPL. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial [Internet]. The Lancet. 2016 ; 387( 10019): 671-678.[citado 2024 maio 03 ] Available from: https://doi.org/10.1016/s0140-6736(15)01021-1Vancouver
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, Fischbach M, Magnusson B, Sterba G, Avcin T, Ferriani VPL. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial [Internet]. The Lancet. 2016 ; 387( 10019): 671-678.[citado 2024 maio 03 ] Available from: https://doi.org/10.1016/s0140-6736(15)01021-1